In particular, among the 293 cases of gastric adenocarcinoma in TCGA database, MYC and CCNE1 amplification was detected in 11.9% and 10.6% patients, respectively, whereas in the CSF samples of our cohort, the MYC and CCNE1 amplification ratios were 46.7% and 53.3%, respectively. This evidence concerns the gene MYC and gastric adenocarcinoma.